Recruiting PHASE2 INTERVENTIONAL 1-arm NCT05343325

The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC

Neoadjuvant Low-dose Radiotherapy, Tislelizumab, Combined With Albumin-bound Paclitaxel and Cisplatin in Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (NeoRTPC02): an Open Label, Single-arm, Phase II Clinical Trial

Sponsor: Dongguan People's Hospital

Conditions Head and Neck Squamous Cell Carcinoma Neoadjuvant Treatment

Interventions Low-dose radiotherapy Tislelizumab

Updated 5 times since 2022 Last updated: Dec 26, 2022 Started: Mar 9, 2022 Primary completion: Mar 31, 2024 Completion: Mar 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Head and Neck Squamous Cell Carcinoma and Neoadjuvant Treatment, this trial is actively recruiting participants. The trial is conducted by Dongguan People's Hospital and has accumulated 5 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Feb 2023 — Jul 2024 [monthly]

Recruiting PHASE2
Nov 2022 — Feb 2023 [monthly]

Recruiting PHASE2
May 2022 — Nov 2022 [monthly]

Recruiting PHASE2

First recorded

Mar 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dongguan People's Hospital
Fifth Affiliated Hospital, Sun Yat-Sen University

Data source: Fifth Affiliated Hospital, Sun Yat-Sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dongguan, China
• Zhuhai, China